Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 6 of 6 publications.

O'Connor G, Pinero Casas M, Basagana X, Lopez Vicente M, Davand P, Torrent M, Martinez-Murciano D, Garcia-Esteban R, Marinelli M, Sunyer J, Julvez J. Corrigendum to "Television viewing duration during childhood and long-association with adolescent neuropsychological outcomes" [Prev. Med. Rep. 4 (2016) 447-452.]. Prev Med Rep. 2021 Mar;21:101305. doi: 10.1016/j.pmedr.2020.101305

Sharp L, McDevitt J, Brown C, Carsin AE, Comber H. Association between smoking at diagnosis and cause-specific survival in patients with rectal cancer: results from a population-based analysis of 10,794 cases. Cancer. 2017 Jul 1;123(13):2543-50. doi: 10.1002/cncr.30583

O'Connor G, Pinero Casas M, Basagana X, Vicente ML, Davand P, Torrent M, Martinez-Murciano D, Garcia-Esteban R, Marinelli M, Sunyer J, Julvez J. Television viewing duration during childhood and long-association with adolescent neuropsychological outcomes. Prev Med Rep. 2016 Aug 15;4:447-52. doi: 10.1016/j.pmedr.2016.08.013

Nastoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor MD, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. Cancer. 2014 Jun 15;120(12):1830-7. doi: 10.1002/cncr.28659

Martin P, Byrtek M, Dawson K, Ziemiecki RM, Friedberg JW, Cerhan JR, Flowers CR, Link BK. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National Lymphocare Study. Cancer. 2013 Dec 1;119(23):4129-36. doi: 10.1002/cncr.28350

Burris HA, Lebrun F, Rugo HS, Beck T, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci J-F, Bauly H, Taran T, Sahmoud T, Noguchi S. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. 2013 Mar 15;119(10):1908-15.